Drugs / pegsitacianine
pegsitacianine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05048082 | Apr → Aug 2022 | lung cancer | OncoNano Medicine, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04950166 | Nov 2021 → Dec 2022 | peritoneal carcinomatosis | OncoNano Medicine, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03735680 | Aug 2019 → Oct 2021 | breast cancer, colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +3 | OncoNano Medicine, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05576974 Comparator | Apr 2024 → Dec 2027 expected | cancer of unknown primary site, head and neck squamous cell carcinoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegsitacianine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950166 ↗ |
| Known as | ONM-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03735680 ↗ |
| Known as | ONM-100 DS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650497 ↗ |
| Modality | Diagnostic / imaging agent | “ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer” NCT03735680 ↗ |
| Route | Intravenous | “1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.” NCT04950166 ↗ |